A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma.

Trial Profile

A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2012

At a glance

  • Drugs Valproic acid (Primary) ; Tazarotene
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Sponsors TopoTarget
  • Most Recent Events

    • 29 Nov 2007 Status changed to completed.
    • 29 Nov 2007 Results have been reported.
    • 13 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top